



Neo-adjuvant chemotherapy for hormone receptor positive breast cancer

This leaflet explains your neo-adjuvant chemotherapy treatment schedule for hormone receptor positive breast cancer. Please use it alongside your Macmillan information leaflet.

What is hormone receptor positive breast cancer?

A hormone receptor positive (HR+) cancer means that oestrogen, progesterone or both female hormones are fuelling the growth of cancer cells.

Neo-adjuvant chemotherapy is a standard treatment for hormone receptor positive breast cancer.

What is neo-adjuvant chemotherapy?

Neo-adjuvant chemotherapy refers to using chemotherapy before other treatments, to shrink the tumour. The drugs used in your individual schedule are Epirubicin, Cyclophosphamide and Docetaxel. You will also get Filgrastim injections to treat neutropenia (low white blood cells) caused by cancer medicines. For details on all treatments and possible side effects, visit www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs.

Your schedule

	Cycle 1 3 weeks	Cycle 2 3 weeks	Cycle 3 3 weeks		
C	† 01		d'1	_	
(Cycles 1-3		Cycles 4-6		
• Day 1: Epirubicin and Cyclophosphamide (EC)			Day 1: Doceta	Day 1: Docetaxel	
Filgrastim injections given for 7 days after each treatment			nent Filgrastim injecti	Filgrastim injections given for 7 days after each treatme	

